Posts for the 'Fosamax' Category
Failure to warn of Fosamax dangers prevents informed decisions
Merck, the manufacturer of Fosamax, continues to minimize the risk of osteonecrosis of the jaw associated with their medication. The failure to provide accurate information regarding this Fosamax danger has deprived women of the opportunity to weigh the risks against the benefits and make an informed decision. Read the rest of this entry »
Fosamax jawbone danger not disclosed in current ads
In this morning’s Washington Post, a letter to the editor criticized the advertisement of Fosamax on television given the risk of jawbone infections. Ronald S. Brown, a professor of oral diagnosis at the Howard University College of Dentistry, stated: Read the rest of this entry »
Occurrence of Fosamax jaw bone decay is likely to increase
Although Fosamax was approved by the FDA in 1995, the first reports of jaw bone decay side effects did not surface until early 2005. The reason for this long delay is that the risk of jaw bone deterioration increases with long term use of the medication. Read the rest of this entry »
